Cervical carcinogenesis associated with the use of combined oral contraceptives: is there a relationship?
- Authors: Klyukina L.A.1, Sosnova E.A.1, Ishchenko A.A.2, Davydov M.M.1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University
- Medical and Rehabilitation Center
- Issue: Vol 10, No 2 (2023)
- Pages: 123-132
- Section: Original study articles
- URL: https://journal-vniispk.ru/2313-8726/article/view/219159
- DOI: https://doi.org/10.17816/2313-8726-2023-10-2-123-132
- ID: 219159
Cite item
Abstract
BACKGROUND: Cervical cancer is one of the leading cancers in women of reproductive age. The etiological role of the human papillomavirus (HPV) in cancer development is long known and undisputed. However, owing to the widespread use of combined oral contraceptives (COCs), scientists actively investigate possible mechanisms of interrelation between sex steroids and HPV in terms of cervical cancer risk.
AIM: This study aimed to assess the risk of cervical cancer in women of reproductive age, depending on the use of COCs for different durations.
MATERIALS AND METHODS: The study included 411 patients of reproductive age who were treated at the Center for Gynecology and Reproductive Technologies of the Russian Ministry of Health and the Department of Oncogynecology at the University Clinical Hospital No. 4 of the I.M. Sechenov First Moscow State Medical University between January 2015 and December 2021. All patients were divided into two groups. The study group included 291 patients with verified cervical cancer, and the control group included 120 patients without cancer.
RESULTS: The study group was significantly more likely to take COCs (56, or 19.2%) than the control group (11, or 6.5%; p=0.018). In addition, the study group had significantly longer treatment durations (p=0.011). Overweight (n = 52, or 17.9%) and grade II obesity (n = 11, or 3.8%, vs. 0; p=0.03) were significantly more common in the study group than in the control group (n = 8, or 4.7%; p=0.003). The result of the multivariate analysis showed that taking COCs negatively affect cervical cancer development (p=0.018; odds ratio (OR) 1.230; CI 1.064–1.423). The receiver operating characteristic analysis revealed that the use of COCs has a high predictive value for determining the risk of cervical cancer (area under the curve, AUC=0.742); the sensitivity and specificity of this predictor were 74.07% and 72.73%, respectively. In the assessment on the effect of duration of COC use on the risk of cervical cancer, the results showed that total use of COCs for over 7 years was associated with a higher risk of cervical cancer development (p=0.010; OR 1.68; CI 1.1–2.5).
CONCLUSIONS: Prescribing COCs in patients with HPV infection requires a personalized approach to consider etiologic factors of cervical cancer and reduce possible carcinogenic risks.
Full Text
##article.viewOnOriginalSite##About the authors
Lidiya A. Klyukina
I.M. Sechenov First Moscow State Medical University
Author for correspondence.
Email: lidiaklyukina@mail.ru
ORCID iD: 0000-0001-7602-4584
post-graduate student
Russian Federation, 8, building 2, Trubetskaya str. Moscow, 119991Elena A. Sosnova
I.M. Sechenov First Moscow State Medical University
Email: sosnova-elena@inbox.ru
ORCID iD: 0000-0002-1732-6870
SPIN-code: 6313-9959
MD, Dr. Sci. (Med.), Professor
Russian Federation, 8, building 2, Trubetskaya str. Moscow, 119991Anton A. Ishchenko
Medical and Rehabilitation Center
Email: ra2001_2001@mail.ru
ORCID iD: 0000-0001-6673-3934
MD, Cand. Sci. (Med.)
Russian Federation, MoscowMikhail M. Davydov
I.M. Sechenov First Moscow State Medical University
Email: mihail-davydov@mail.ru
ORCID iD: 0000-0001-5038-9307
MD, Dr. Sci. (Med.), Corresponding Member of the Russian Academy of Sciences, Head of the Department of Oncology
Russian Federation, 8, building 2, Trubetskaya str. Moscow, 119991References
- IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum. 2007:90:1–636.
- Schottenfeld D, Fraumeni JF. Cancer Epidemiology and Prevention. Thun M, Linet MS, Cerhan JR, Haiman ChA, Schottenfeld D, editors. Oxford: Oxford University Press; 2017.
- Moodley M, Moodley J, Chetty R, Herrington CS. The role of steroid contraceptive hormones in the pathogenesis of invasive cervical cancer: a review. Int J Gynecol Cancer. 2003;13(2):103–110. doi: 10.1046/j.1525-1438.2003.13030.x
- Association of Oncologists of Russia, Russian Society of Clinical Oncology, Russian society of specialists in the prevention and treatment of tumors of the reproductive system. Cervical cancer. Clinical recommendations. Ministry of Health of the Russian Federation; 2020. Available from: https://oncology.ru/specialist/treatment/references/actual/537.pdf?ysclid=lfh6zcuo2e322127604 (In Russ).
- Chiantore MV, Mangino G, Iuliano M, et al. Human Papillomavirus and carcinogenesis: Novel mechanisms of cell communication involving extracellular vesicles. Cytokine Growth Factor Rev. 2020;51:92–98. doi: 10.1016/j.cytogfr.2019.12.009
- Pirog EC. Cervical adenocarcinoma: diagnosis of human papillomavirus-positive and human papillomavirus-negative tumors. Arch Pathol Lab Med. 2017;141(12):1653–1667.doi: 10.5858/arpa.2016-0356-RA
- Veljkovic M, Veljkovic S. The risk of breast cervical, endometrial and ovarian cancer in oral contraceptive users. Med Pregl. 2010;63(910):657–661. doi: 10.2298/mpns1010657v
- Volkov VG. Hormonal contraception and cervical cancer. Journal of New Medical Technologies. Thematic issue “Problems of clinical medicine in the aspect of environmental and occupational risk”. 2001;VIII(3):96–98. (In Russ).
- Bright PL, Turner AN, Morrison CS, et al. Hormonal contraception and area of cervical ectopy: a longitudinal assessment. Contraception. 2011;84(5):512–519. doi: 10.1016/j.contraception.2011.02.002
- Samir R, Asplund A, Tot T, et al. Oral contraceptive and progestin-only use correlates to tissue tumor marker expression in women with cervical intraepithelial neoplasia. Contraception. 2012;85(3):288–293. doi: 10.1016/j.contraception.2011.09.001
- Young JL, Jazaeri AA, Darus CJ, Modesitt SC. Cyclooxygenase-2 in cervical neoplasia: a review. Gynecol Oncol. 2008;109(1):140−145. doi: 10.1016/j.ygyno.2008.01.008
- Ryu HS, Chang KH, Yang HW, et al. High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol. 2000;76(3):320−325.doi: 10.1006/gyno.1999.5690
- Kiselev VI, Ashrafyan LA, Budarina SO, et al. Etiological role of human papillomavirus in the development of cervical cancer: genetic and pathogenetic mechanisms, possibilities of therapy and prevention. Consilium Medicum. Ginekologiya. 2004;6(4):174. (In Russ).
- Chiantore MV, Mangino G, Iuliano M, et al. Human Papillomavirus and carcinogenesis: Novel mechanisms of cell communication involving extracellular vesicles. Cytokine Growth Factor Rev. 2020;51:92–98. doi: 10.1016/j.cytogfr.2019.12.009
- Ramachandran B. Functional association of oestrogen receptors with HPV infection in cervical carcinogenesis. Endocr Relat Cancer. 2017;24(4):R99–R108. doi: 10.1530/ERC-16-0571
- Gadducci A, Barsotti C, Cosio S, Domenici L, Riccardo Genazzani A. Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature. Gynecol Endocrinol. 2011;27(8):597–604.doi: 10.3109/09513590.2011.558953
- Fischer S, Kuebler U, Abbruzzese E, et al. Endogenous oestradiol and progesterone as predictors of oncogenic human papillomavirus (HPV) persistence. BMC Cancer. 2022;22(1):145.doi: 10.1186/s12885-022-09247-3
- Marks MA, Gravitt PE, Burk RD, et al. Progesterone and 17beta-estradiol enhance regulatory responses to human papillomavirus type 16 virus-like particles in peripheral blood mononuclear cells from healthy women. Clin Vaccine Immunol. 2010;17(4):609–617.doi: 10.1128/CVI.00441-09
- Hellberg D. Sex Steroids and Cervical Cancer. Anticancer Res. 2012;32(8):3045–3054.
- Iversen L, Fielding Sh, Lidegaard Ø, Hannaford PhC. Contemporary hormonal contraception and cervical cancer in women of reproductive age. Int J Cancer. 2021;149(4). doi: 10.1002/ijc.33585
- International Collaboration of Epidemiological Studies of Cervical Cancer; Appleby P, Beral V, Berrington de González A, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007;370(9599):1609–1621.doi: 10.1016/S0140-6736(07)61684-5
- Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev. 2013;22(11):1931–1943. doi: 10.1158/1055-9965.EPI-13-0298
- Smith JS, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet (London, Engl). 2003;361(9364):1159–1167.doi: 10.1016/s0140-6736 (03)12949-2.
Supplementary files
